Mice expressing tau mutations such as P301L or P301S have been extensively used to investigate how tau aggregation leads to neuronal dysfunction, synaptic loss, and cognitive decline, recapitulating the tau pathology seen in AD patients 137. The gene discussed is MAPT; the disease is Alzheimer disease.